Business Context and Reporting Period
This Form 8-K Current Report was filed by IRADIMED CORPORATION on January 22, 2019. The filing addresses a regulatory event concerning the company's 3880 MRI compatible patient vital signs monitoring systems in European Commission (EC) markets.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific operational event rather than periodic financial results.
Material Changes and Events
On January 22, 2019, the Company announced a temporary suspension of sales for its 3880 MRI compatible patient vital signs monitoring systems in EC markets. This action was taken because the CE Mark for this specific product expired on January 17, 2019, following a technical non-conformity identified by the Notified Body, UL International Ltd. The non-conformity relates to clinical evaluation reporting requirements under new EU guidance, not to safety, effectiveness, or performance issues.
- Scope of Suspension: Applies only to the 3880 monitoring system in markets requiring a CE Mark.
- Exclusions: Sales in the U.S. and non-CE markets are unaffected. Shipments of MRI compatible IV infusion pumps, accessories, disposables, and services continue normally.
- Resolution Timeline: UL issued a temporary EC Certificate excluding the 3880 system for six months. The Company expects to cure the non-conformity and resume CE Mark usage within this period.
Outlook, Risks, and Management Commentary
Management states the suspension is a compliance measure to address documentation requirements and is not indicative of product failure. The Company anticipates resolving the issue within the six-month temporary certificate window.
Forward-looking statements in the filing highlight several risks, including:
- Uncertainty regarding the ability to receive an EC Certificate or CE Mark for existing products.
- Reliance on a single product line.
- Potential disruptions in the supply chain.
- Regulatory actions by the FDA or other bodies that could delay or suspend sales.
Investor Verification Checklist
- Confirm the specific revenue exposure of the 3880 monitoring system to European markets versus total company revenue.
- Verify the timeline for submitting the corrected clinical evaluation report to UL International Ltd.
- Monitor for any updates on the six-month temporary certificate status and potential extension needs.
- Review subsequent filings for any impact on quarterly guidance or financial results due to the suspension.